|
|
Article: Market for Multiple Myeloma Therapeutics in the US to Reach $4.0 Billion by 2015, According to New Report by Global Industry Analysts.(Industry overview)
- Article from:
- PRWeb
- Article date:
- April 14, 2009
CopyrightCOPYRIGHT 2009 COMTEX News Network, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
San Jose, CA, Apr 14, 2009 (PRWeb.com via COMTEX) -- Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Drugs that are expected to be launched in the coming years include - Doxil, Perifisone, ZIO-101, and Tanespimycin. These would be used in combination with any of the three major drugs - Revlimid, Velcade, and Thalomid. Although patients today have a broader choice of ...
Related newspaper, magazine, and journal articles:
|